Type 1 diabetes mellitus. Type 1 diabetes mellitus
Conditions
Interventions
Intervention 1: The intervention group will receive a probiotic supplement capsule. This supplement will be produced by the tak gene zist company, which consists of 6 bacterial strains including Lacto
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
7 Years to 18 Years
Inclusion criteria
Inclusion criteria: Having type 1 diabetes (fasting blood sugar greater than 125 mg / dL and HbA1C greater than 6.5% if confirmed by an endocrinologist) Age over 7 and under 18 years At least one year after developing type 1 diabetes Willingness to participate in the study
Exclusion criteria
Exclusion criteria: Having liver, kidney, inflammatory, or immunodeficiency diseases Taking antibiotics over the last two months Consuming foods containing probiotics or probiotic supplements over the past month Taking dietary supplements or non-steroid anti-inflammatory drugs during 1 month before the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hemoglobin A1c (HbA1C). Timepoint: At the beginning of the study and at the end of the study (after 12 weeks). Method of measurement: Enzymatically using commercial kits.;Fasting blood sugar level (FBS). Timepoint: At the beginning of the study and at the end of the study (after 12 weeks). Method of measurement: By glucose oxidase method and using commercial kits.;Serum triglyceride levels (TG). Timepoint: At the beginning of the study and at the end of the study (after 12 weeks). Method of measurement: Using glycerol phosphate oxidase and commercial kits.;Serum high-density lipoprotein cholesterol level (HDL-C). Timepoint: At the beginning of the study and at the end of the study (after 12 weeks). Method of measurement: HDL-C concentration after deposition of lipoproteins with apo lipoprotein B.;Total cholesterol. Timepoint: At the beginning of the study and at the end of the study (after 12 weeks). Method of measurement: By cholesterol oxidase and cholesterol esterase methods and using commercial kits.;Serum low-density lipoprotein cholesterol level (LDL-C). Timepoint: At the beginning of the study and at the end of the study (after 12 weeks). Method of measurement: Using the Friedewald formula.;Number of units of injection insulin. Timepoint: At the beginning of the study and at the end of the study (after 12 weeks). Method of measurement: Questions and registrations.;Blood pressure. Timepoint: At the beginning of the study and at the end of the study (after 12 weeks). Method of measurement: Sphygmomanometer.;Anthropometric indicators. Timepoint: At the beginning of the study and at the end of the study (after 12 weeks). Method of measurement: Meters, scales. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSaeedeh Nourimajd
Tehran University of Medical Sciences
Outcome results
None listed